Cartesian Therapeutics, Inc. (RNAC) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$92.6M

EPS$-5.02

Market Cap$163.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Carsten Brunn

CEO & Executive Director

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The companyâs lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Founded: 2007
Employees: 75
Headquarters

⚡

Core Efficiency

ROE?

73.33%

ROA?

-31.23%

D/E Ratio?

-3.35

📊

Profitability Ratios

Current Ratio?

8.65

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 27, 2026 (in 109 days)

Annual Report (10-K) — Based on filing pattern

Jul 27, 2026

Predicted10-K

Mar 9, 2026

10-KQ4 20259d after period end

Nov 6, 2025

10-QQ3 20256d after period end

Aug 7, 2025

10-QQ2 20256d after period end

May 8, 2025

10-QQ1 20258d after period end

Mar 13, 2025

10-KQ4 202413d after period end

Nov 7, 2024

10-QQ3 20246d after period end

Aug 8, 2024

10-QQ2 20241d after period end

May 8, 2024

10-QQ1 20245d after period end

Loading company sections...

Cartesian Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness